Home Clinical trials For patients Ovary BEHOLD-2

BEHOLD-2

A Phase I/II Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 in Combination with Anti-Cancer Agents in Participants with Advanced Solid Tumors

Open
Trial drug
GSK5733584 + bevacizumab
Grade
High grade, Low grade
Prior lines
1, 2, 3, 4
Histology
Serous, Mucinous Endometrioid Clear-cell Carcinocarcoma
Platin
Platinum resistant
Secondary platinum refractory
Platinum sensitive
Primary platinum refractory
Phase
I/II

Treatment

The treatment option in this study is GSK5733584 + bevacizumab.

 

Treatment duration

The treatment can continue until disease progression, unacceptable toxicities or until you decide to stop.

 

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.